Can Competitors
| CANF Stock | USD 4.17 0.23 5.23% |
Can Fite vs Calidi Biotherapeutics Correlation
Very poor diversification
The correlation between Can Fite Biopharma and CLDI is 0.83 (i.e., Very poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Can Fite Biopharma and CLDI in the same portfolio, assuming nothing else is changed.
Moving together with Can Stock
Moving against Can Stock
| 0.91 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.73 | DSGN | Design Therapeutics | PairCorr |
| 0.67 | ENGN | enGene Holdings Common | PairCorr |
| 0.63 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.57 | 63E | ONWARD MEDICAL BV | PairCorr |
Can Fite Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Can Fite and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Can and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Can Fite Biopharma does not affect the price movement of the other competitor.
Risk-Adjusted Indicators
There is a big difference between Can Stock performing well and Can Fite Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Can Fite's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| KZIA | 8.15 | (0.30) | 0.01 | 0.03 | 10.28 | 14.69 | 78.79 | |||
| CNSP | 3.61 | (0.93) | 0.00 | (0.97) | 0.00 | 7.22 | 31.54 | |||
| CMND | 7.17 | (3.98) | 0.00 | 1.93 | 0.00 | 11.60 | 56.34 | |||
| SNGX | 3.54 | (0.31) | 0.00 | (0.08) | 0.00 | 8.16 | 30.10 | |||
| GRI | 7.79 | (3.66) | 0.00 | 18.57 | 0.00 | 11.88 | 77.14 | |||
| OGEN | 3.59 | (0.84) | 0.00 | (0.45) | 0.00 | 7.32 | 24.70 | |||
| SILO | 3.81 | (0.88) | 0.00 | (0.31) | 0.00 | 8.33 | 24.79 | |||
| BDRX | 8.72 | (1.14) | 0.00 | (0.54) | 0.00 | 11.45 | 128.35 | |||
| JAGX | 7.30 | (1.12) | 0.00 | (0.21) | 0.00 | 10.14 | 125.57 | |||
| CLDI | 2.68 | (1.11) | 0.00 | (0.85) | 0.00 | 4.48 | 18.21 |
Cross Equities Net Income Analysis
Compare Can Fite Biopharma and related stocks such as Kazia Therapeutics, CNS Pharmaceuticals, and Clearmind Medicine Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KZIA | (17.1 M) | 1.3 M | (1 M) | (7.5 M) | (7.1 M) | (12.1 M) | (10.7 M) | (6 M) | (10.3 M) | (12.5 M) | (8.4 M) | (25 M) | (20.5 M) | (26.8 M) | (20.7 M) | (23.8 M) | (25 M) |
| CNSP | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (7.4 M) | (3.9 M) | (9.5 M) | (14.5 M) | (15.3 M) | (18.9 M) | (14.9 M) | (13.4 M) | (14 M) |
| CMND | (33.2 K) | (33.2 K) | (33.2 K) | (33.2 K) | (46.9 K) | (24.2 K) | (6.5 K) | (194.5 K) | (105.3 K) | (233.2 K) | (3.7 M) | (9.9 M) | (11.9 M) | (7.3 M) | (5.4 M) | (4.9 M) | (5.1 M) |
| SNGX | (1.2 M) | (2.4 M) | (4.2 M) | (10.1 M) | (6.7 M) | (7.8 M) | (3.2 M) | (7.1 M) | (8.9 M) | (9.4 M) | (17.7 M) | (12.6 M) | (13.8 M) | (6.1 M) | (8.3 M) | (7.4 M) | (7.8 M) |
| OGEN | (1.7 M) | (7.7 M) | (13.1 M) | (16.1 M) | (5.8 M) | (11.7 M) | (7 M) | (6.7 M) | (9.9 M) | (15.6 M) | (26.4 M) | (15.7 M) | (14.3 M) | (20.7 M) | (10.6 M) | (9.5 M) | (10 M) |
| BDRX | (4 M) | (4 M) | (4 M) | (4.1 M) | (8.8 M) | (10.1 M) | (6.2 M) | (11.7 M) | (10.4 M) | (10.1 M) | (22.2 M) | (5.5 M) | (7.7 M) | (7.1 M) | (5.7 M) | (5.2 M) | (5.4 M) |
| JAGX | (25.5 M) | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (16.3 M) | (14.7 M) | (22 M) | (32.1 M) | (38.5 M) | (33.8 M) | (52.6 M) | (47.5 M) | (41.3 M) | (38.5 M) | (34.6 M) | (36.4 M) |
| CLDI | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (10.9 M) | (25.4 M) | (29.2 M) | (22.1 M) | (19.9 M) | (20.9 M) |
Can Fite Biopharma and related stocks such as Kazia Therapeutics, CNS Pharmaceuticals, and Clearmind Medicine Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Can Fite Biopharma financial statement analysis. It represents the amount of money remaining after all of Can Fite Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Can Fite Competitive Analysis
The better you understand Can Fite competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Can Fite's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Can Fite's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Can Fite Competition Performance Charts
Five steps to successful analysis of Can Fite Competition
Can Fite's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Can Fite Biopharma in relation to its competition. Can Fite's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Can Fite in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Can Fite's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Can Fite Biopharma, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Can Fite position
In addition to having Can Fite in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Diversified Assets Thematic Idea Now
Diversified Assets
Pablicly traded close-end funds and other entities backed by different types of diversified investments. The Diversified Assets theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Diversified Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Can Fite Correlation with its peers. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Can Biotechnology industry sustain growth momentum? Does Can have expansion opportunities? Factors like these will boost the valuation of Can Fite. Projected growth potential of Can fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Can Fite demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding Can Fite Biopharma requires distinguishing between market price and book value, where the latter reflects Can's accounting equity. The concept of intrinsic value - what Can Fite's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Can Fite's price substantially above or below its fundamental value.
It's important to distinguish between Can Fite's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Can Fite should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Can Fite's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.